Organigram Global Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Organigram Global Inc (OGI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Organigram Global Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 199M vs 3,028M combined for tracked competitors (6.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-44.4%) for its tracked peer group.
- Growth: Organigram Global Inc generated 62.2% revenue growth year over year in Q4 2025, vs 6.8% for its tracked competitors combined.
- Profitability: Its -9.6% net margin compares with -1.5% for the peer group.
- Scale: Organigram Global Inc ranks #302 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Organigram Global Inc accounted for 32.1% of combined revenue among its tracked peer group, up from 23.7% a year earlier.
- Peer differentiation: Revenue per employee of $0.25M compares with $0.40M for the peer group (0.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OGI Sales vs. its Competitors, Q4 2025
Organigram Global Inc reported revenue growth of 62.15 % year on year in Q4 2025, above its competitors' combined revenue growth of 6.81 %.
With a net margin of -9.55 %, Organigram Global Inc reported lower profitability than its competitors (-1.48 %).
Organigram Global Inc generated 32.05 % of the combined sales of its peer group, up from 23.70 % a year earlier.
Organigram Global Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Organigram Global Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Organigram Global Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Organigram Global Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 62.2% for Organigram Global Inc. Organigram Global Inc's share of combined industry revenue moved from 0.02% to 0.03%, a gain of 0.01 percentage points.
Organigram Global Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Organigram Global Inc | No | Yes | Yes | No |
| Competitors combined (24) | ||||
| High-Confidence Competitors (1) | - | - | - | |
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OGI Stock Performance relative to its Competitors
OGI Stock Performance relative to High-Confidence Competitors
OGI Stock Performance relative to Similar-Size Competitors
OGI Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Intercure Ltd | 282.9% | Outperformed |
| 2 | Lexaria Bioscience Corp | 282.9% | Outperformed |
| 3 | Cronos Group Inc | 282.9% | Outperformed |
| 4 | Village Farms International Inc | 282.9% | Outperformed |
| 5 | Growgeneration Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Organigram Global Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Organigram Global Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Organigram Global Inc | - | 198.53 |
| Cronos Group Inc | 1,277.08 | 259.21 |
| Tilray Brands Inc | 452.36 | 914.63 |
| Canopy Growth Corporation | 392.33 | 323.17 |
| Village Farms International Inc | 382.89 | 230.57 |
| Sndl Inc | 356.11 | 724.94 |
| SUBTOTAL | 3,114.95 | 3,610.81 |
Sign in to see all competitors of Organigram Global Inc .
Sources: Organigram Global Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Organigram Global Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Organigram Global Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medbox, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Organigram Global Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Organigram Global Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Tilray Brands Inc | Distribution Business 33.05 % |
| Canopy Growth Corporation | Storz and Bickel 58.69 % |
| Village Farms International Inc | Cannabis Business 83.66 % |
| Growgeneration Corp | Cultivation and Gardening 84.52 % |
| General Cannabis Corp | Retail Segment 99.66 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Organigram Global Inc .
Organigram Global Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Organigram Global Inc | - | 248,168 | -23,707 |
| Cronos Group Inc | 1,277 | 424,938 | 129,843 |
| Tilray Brands Inc | 452 | 254,418 | -29,251 |
| Canopy Growth Corporation | 392 | 286,499 | -156,381 |
| Village Farms International Inc | 383 | 204,409 | 20,304 |
| Sndl Inc | 356 | - | - |
| PEERS TOTAL | 3,115 | 404,778 | -61,757 |
Sign in to see all peers for Organigram Global Inc .
Organigram Global Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cronos Group Inc | Canada 56.07 % |
| Tilray Brands Inc | EMEA 39.41 % |
| Zerostack Corp | DE 92.55 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Organigram Global Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Organigram Global Inc's industry classification, broader than the peer set above. Market cap in millions of $.Organigram Global Inc ranks #302 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 302 | Organigram Global Inc | 83 | 0.00 % |
Market cap and industry share for the rest of Organigram Global Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Organigram Global Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 297 | Tenax Therapeutics Inc | 93 | -74.72 % |
| 298 | Biomea Fusion Inc | 93 | -38.58 % |
| 299 | Talphera Inc | 91 | 31.87 % |
| 300 | Acrivon Therapeutics Inc | 87 | 25.16 % |
| 301 | Longeveron Inc | 1,234 | 12.3% |
| 302 | Organigram Global Inc | 83 | -36.39 % |
| 303 | Oncolytics Biotech Inc | 1,234 | 12.3% |
| 304 | Neonc Technologies Holdings Inc | 1,234 | 12.3% |
| 305 | Lifevantage Corp | 1,234 | 12.3% |
| 306 | Zomedica Corp | 1,234 | 12.3% |
| 307 | Pmv Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Organigram Global Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Organigram Global Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 34.81 % | 64.89 % (avg) | -30.1 pp |
| Operating Margin | -5.90 % | industry median | +36.6 pp |
| EBITDA Margin | -14.87 % | -7.21 % (avg) | -7.7 pp |
| Capital Intensity (Capex / Revenue) | 6.57 % | 4.92 % (avg) | +1.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Organigram Global Inc's Strategic Group Map
Every company in Organigram Global Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Organigram Global Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Organigram Global Inc's BCG Growth-Share Matrix
Relative market share (vs Organigram Global Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Organigram Global Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Organigram Global Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 6.57 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Organigram Global Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Organigram Global Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Organigram Global Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Organigram Global Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Organigram Global Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 36.6 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 24.7 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of tracked competitors (39.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-44.4% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Organigram Global Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Organigram Global Inc | 0.22 | 2.26 | 0.04 |
| Cronos Group Inc | 15.24 | 19.71 | - |
| Tilray Brands Inc | 0.83 | 2.49 | 0.22 |
| Canopy Growth Corporation | 2.02 | 3.43 | 0.42 |
| Village Farms International Inc | 1.38 | 2.89 | 0.13 |
| Sndl Inc | 2.74 | 4.88 | 40.21 |
Sign in to see all peers for Organigram Global Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Organigram Global Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Organigram Global Inc | Q3 2025 | +62.2 % | - |
| Cronos Group Inc | Q2 2026 | +269.5 % | - |
| Tilray Brands Inc | Q2 2026 | +24.9 % | - |
| Canopy Growth Corporation | Q2 2026 | +409.8 % | - |
| Village Farms International Inc | Q2 2026 | +6.8 % | -72.6 % |
| Sndl Inc | Q4 2025 | +2.8 % | - |
| PEERS TOTAL | +43.4 % | - |
Sign in to see all peers for Organigram Global Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Organigram Global Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Organigram Global Inc | Q3 2025 | +51.7 % | +259.8 % |
| Cronos Group Inc | Q2 2026 | +66.5 % | -80.8 % |
| Tilray Brands Inc | Q2 2026 | +21.0 % | - |
| Canopy Growth Corporation | Q2 2026 | +256.1 % | -53.1 % |
| Village Farms International Inc | Q2 2026 | -9.5 % | +54.3 % |
| Sndl Inc | Q4 2025 | +1.1 % | +48.7 % |
Sign in to see all peers for Organigram Global Inc .
Organigram Global Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Organigram Global Inc | - | - | - |
| Cronos Group Inc | 6.70% | 6.90% | 7.25% |
| Tilray Brands Inc | - | - | - |
| Canopy Growth Corporation | - | - | - |
| Village Farms International Inc | 5.48% | 6.25% | 7.63% |
| Sndl Inc | - | - | - |
Sign in to see all peers for Organigram Global Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Organigram Global Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Organigram Global Inc | - | - |
| Cronos Group Inc | 16.21 | 4.93 |
| Tilray Brands Inc | - | 0.49 |
| Canopy Growth Corporation | - | 1.21 |
| Village Farms International Inc | 17.28 | 1.66 |
| Sndl Inc | - | 0.49 |
| PEERS AVERAGE | - | 0.86 |
Sign in to see all peers for Organigram Global Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.